Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 12/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566975 | 0.84 | IGF1R (0.57) | NTRK1IGF1RNUAK1CCNA2CDK2 | |
| SCHEMBL2570591 | 0.82 | IGF1R (0.59) | NTRK1IGF1RNUAK1CCNA2CDK2 | |
| SCHEMBL219252 | 0.81 | IGF1R (0.66) | NTRK1IGF1RCCNA2CDK2 | |
| SCHEMBL1164335 | 0.79 | IGF1R (0.64) | NTRK1IGF1RCCNA2CDK2 | |
| SCHEMBL12653359 | 0.79 | IGF1R (0.64) | NTRK1IGF1RCCNA2CDK2 | |
| SCHEMBL1165123 | 0.76 | IGF1R (0.67) | NTRK1IGF1RCCNA2CDK2 | |
| SCHEMBL2319952 | 0.75 | PIK3C3 (0.55) | IGF1RCCNA2CDK2 | |
| SCHEMBL27718573 | 0.75 | IGF1R (0.60) | NTRK1IGF1RCCNA2CDK2 | |
| SCHEMBL5029662 | 0.75 | NTRK1 (1.00) | NTRK1NUAK1 | |
| SCHEMBL2489276 | 0.75 | JAK2 (0.63) | NTRK1IGF1RCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| US-8835465-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2014-09-16 | — | — | US | disclosed |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8324252-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2012-12-04 | — | — | US | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | NTRK1 86/4885IGF1R 132/4885NUAK1 168/4885 |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K2 | NTRK1 1107/4885IGF1R 748/4885NUAK1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.